BioSpace News Archive

Diversified biotechnology company CCM Biosciences launched from stealth with more than ten drug programs, many of which originated from CCM Biosciences’ proprietary drug discovery platforms.

The 9th Annual BioNTX iC³ Life Science Summit is only one month away! On September 28 and Friday, September 29, iC³ brings North Texas bioscience and healthcare innovation leaders together for a two-day event.

Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 21st Annual Global Healthcare Conference, Sept. 11-12, 2023.

Northwest Biotherapeutics announces that it plans to submit a Marketing Authorization Application in the U.K., to the Medicines and Healthcare Products Regulatory Agency, for commercial approval of the Company’s DCVax®-L treatment for glioblastoma.

Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the New Brunswick Drug Plan formulary and the Nova Scotia Formulary for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.

Viva Biotech Holdings Group announced that during the period ended June 30, 2023, the revenue of the Group during the Reporting Period increased by approximately 3.0% from RMB1,108.7 million for the corresponding period of last year to RMB1,142.2 million; and the gross profit increased by approximately 17.7% from RMB345.0 million for the corresponding period of last year to RMB406.0 million.

Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announces that a new U.S. patent which covers CAMCEVI® (leuprolide mesylate) and its labeled indication is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as “the Orange Book”.

City of Hope announced the appointment of Marcel van den Brink, M.D., Ph.D., as president of City of Hope Los Angeles and National Medical Center, chief physician executive and the Deana and Steve Campbell Chief Physician Executive Distinguished Chair in honor of Alexandra Levine, M.D.

Kiora Pharmaceuticals (NASDAQ: KPRX) invites you to participate in a webinar highlighting the progress of molecular photoswitches in retinitis pigmentosa and the future

Spark Biomedical, Inc. was awarded a $1.15M Phase II grant to develop a Transcutaneous Auricular Neurostimulation device, Sparrow® Hawk, to address the adverse effects of acute stress reaction.